With the recent development of single B-cell cloning techniques, an increasing number of human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing antibodies have been isolated since 2009. However, knowledge regarding HIV-1-specific B cells in vivo is limited. In this study, an HIV-1-specific B-cell line was established using healthy PBMC donors by the highly efficient Epstein-Barr virus transformation method to generate immortalized human naïve B-cell libraries. The enrichment of HIV-1 envelope-specific B cells was observed after four rounds of cell panning with the HIV-1 envelope glycoprotein. An HIV-1 envelope-specific stable B-cell line (LCL-P4) was generated. Although this cell line acquired a lymphoblastic phenotype, no expression was observed for activation-induced cytidine deaminase, an enzyme responsible for initiating somatic hypermutation and class switch recombination in B cells. This study describes a method that enables fast isolation of HIV-1-specific B cells, and this approach may extend to isolating other B-cell-specific antigens for further experiments.
INTRODUCTION
Among human immunodeficiency virus type 1 (HIV-1)-infected individuals, approximately 20 % generate broadly neutralizing antibodies (bNAbs) for 2-4 years after infection [1] . Since 2009, a large number of bNAbs have been isolated using single B-cell gene cloning and validation by neutralization screening [2] . Additional bNAbs have also been obtained through probe-based B-cell isolation methods [3] . These bNAbs show promising prophylactic and therapeutic values in animal models [4, 5] , though one of the bNAbs, VRC01, only slightly delayed viral rebound after stopping antiretroviral therapy in two clinical trials by administering purified antibodies [6] . However, induction of bNAbs has not been achieved by any vaccine candidates so far [7] . Traditional strategies for vaccine development have relied on attenuated or killed virus particles. Protein subunit preparations for a homologous 'prime-boost' strategy have also been attempted, which assumed that antigens recognized by naïve B cells in the priming phase would be the same as those recognized by memory B cells during a vaccine boost.
Although great successes have been achieved with these strategies to combat infectious diseases in the past century [8, 9] , their use in the development of HIV-1 vaccines has failed to elicit effective antibodies.
The unusual characteristics of bNAbs have provided some insights into overcoming these limitations. Extraordinarily high mutation frequencies in the V(D)J fragments (15-35 %) are typically observed in bNAbs. These higher-than-average levels occur during the secondary humoral immune response (6 %) [10, 11] . This suggests that B-cell activation and affinity maturation may be induced by different antigens [12] . Recent findings also support this hypothesis because putative bNAbs in the germline do not bind recombinant HIV-1 envelopes [13, 14] . In light of this, we have identified five non-HIV-derived polypeptides that bind putative germline bNAbs. Interestingly, these peptides could serve as primary immunogens to initiate humoral immune responses, leading to the discovery of cross-clade HIV-specific neutralizing antibodies produced in rabbits [15] . To investigate whether naïve B cells from healthy individuals stimulated by non-HIV-1 immunogens can produce bNAbs against HIV-1, we established a B-cell line. An HIV-1 envelope glycoprotein-recognizing B-cell clone was isolated from healthy donors. To establish the B-cell line, a traditional EpsteinBarr virus (EBV) transformation method was optimized to provide higher efficiency. This allowed the establishment of a diversity of human naïve B-cell libraries, which could be panned following stimulation. Next, an HIV-1-specific Bcell line was generated after four rounds of cell panning with the HIV-1 envelope. This cell line, termed LCL-P4, displayed a limited number of mutations in both VH and VL. This naïve B-cell line can be used for future stimulation experiments. Therefore, this study provides a useful method that facilitates rapid isolation of HIV-1-specific B cells.
RESULTS

Generation of a human naïve B-cell library
The procedure for generating HIV-1 naïve B cells from PBMCs from healthy donors is shown in Fig. 1 . PBMCs were first isolated from healthy buffy coat donors, and naïve B cells were purified using magnetic beads. Since primary B cells could not survive in long-term culture in vitro, EBV transformation was performed. However, because the transformation efficiency is generally low [16] , this method was further optimized using spinfection in the presence of certain cytokines. To construct the naïve B-cell library, 8Â10
7 naïve B cells were isolated from 16 healthy donors. They underwent two rounds of negative selection to remove non-B cells and memory B cells (Fig. 2a) . The efficiency was evaluated by assessing lymphoblastoid cell outgrowths on day 21 (Table 1) . One colony was regarded as one successful transformation. The transformation efficiency was estimated to be approximately 7.8 %, which was significantly higher than the traditional EBV-based method (approximately 2-3 %). The final size of the naïve B-cell library was estimated to be 5.8Â10 6 based upon counts of cell clumps.
Enrichment of HIV-1-specific B cells by panning with gp140 YU2 trimers An antigen-based B-cell enrichment method has been previously developed using magnetic beads [17] . Using this approach, four rounds of cell panning with magnetic beads were performed (Fig. 1) . The enrichment of HIV-1-specific B cells was determined following each round of panning using gp140 YU2 (Fig. 2b) . Biotinylated KLH was used as a negative control to exclude non-specific binding caused by biotinylation. Since the diameter of M-280 beads was about 2.8 µm, the binding of B cells to beads could be visualized under brightfield microscopy during the panning process (Fig. 2c) .
Characterization of the LCL-P4 antibody After four rounds of panning with gp140 YU2 in vitro, B cells appeared to be a homogenous population based on sequencing (Fig. 3) . We selected 30 B-cell clones, and the VH and VL genes were cloned and sequenced. The results showed that these cells arose from a single clone. This B-cell line was termed LCL-P4, which has a homology rate of 96.53 % on VH and 93.19 % on VK, respectively, when compared with the germline segment (Fig. 3a) . Mutations were found in both the complementarity determining regions (CDRs) and framework regions (FWRs) of the LCL-P4 cell line (Fig. 3b) . To determine whether class switch recombination (CSR) occurred during screening, soluble antibody subtypes in the supernatant were examined by ELISA after each round of panning. Results showed that CSR did not occur, and the majority of antibodies were IgM (Fig. 4a) . Next, to investigate whether LCL-P4 is HIV strain specific, the binding activity to gp140 YU2 and gp140 SF162 for the supernatant of this cell line was examined. Results showed that LCL-P4 bound both gp140 SF162 and gp140 YU2 trimers ( Fig. 4b-d ) but failed to bind BSA. IgG antibodies purified from the supernatant also bound both gp140 SF162 and gp140 YU2 trimers ( Fig. 4e-f ). However, LCL-P4 did not compete with CD4bs antibody b12 for gp140 YU2 binding, indicating that LCL-P4 does not target CD4bs (data not shown).
Characterization of the LCL-P4 cell line LCL-P4 cells bound to gp140 YU2 in a dose-dependent manner in flow-cytometry-based binding assays (Fig. 5a ). LCL-P4 cells assumed a lymphoblastoid phenotype with cell size and upregulation of activation makers [18] . The expression of the co-stimulatory molecules CD83 and CD86 was found to be highly upregulated in LCL-P4 cells (Fig. 5b) . Furthermore, LCL-P4 cells expressed high levels of MHC-II, indicating that these activated B cells may serve as antigenpresenting cells. Consistent with the ELISA data, CSR did not occur. IgM was expressed on the cell surface, but not IgG or IgA (Fig. 5b ). Next, we investigated which B-cell subpopulation LCL-P4 belonged to by using a human B-cell mature classification system by flow cytometry [19, 20] . The results showed that LCL-P4 cells acquired a germinal centre-like phenotype (CD19 5b) . B cells usually undergo somatic hypermutation and CSR in the germinal centre of lymphoid organs, which are initiated by activation-induced cytidine deaminase (AID) in vivo [18] . However, AID was not detected in LCL-P4 cells by Western blotting (Fig. 5c ).
DISCUSSION
In this study, we report an efficient procedure for isolation of HIV-1-specific naïve B cells from healthy donors. To our knowledge, this is the first HIV-1-specific naïve B-cell line generated that expresses an HIV-1 envelope-recognizing antibody. The isolation of naïve B cells supports the hypothesis that certain B cells from healthy donors can bind and be activated by HIV-1 envelopes. In order to understand how HIV-1-specific naïve B cells were first activated, it is important to have models of stable naïve B cells that express an antigen-specific B-cell receptor. Previous studies addressed this by introducing mature or germline bNAbs into B-cell lines to assess their binding and activation by various HIV-1 recombinant envelopes [13, 18] . With our method, HIV-1 envelope-specific naïve B cells can be directly isolated in vitro from individuals, which better facilitates the study of B-cell activation and germline antibodies.
One difficulty encountered in this study was the need to increase B-cell immortalization efficiency. Unlike mouse B cells, human B cells were resistant to immortalization using hybridoma technology, and EBV transformation is the only established method for long-term human B-cell immortalization [21] . One study used a Toll-like receptor 9 agonist (CpG DNA), which synergistically increased proliferation and activation of B cells after EBV infection [22] . Furthermore, EBV transformation efficiency was increased to 0.1-2 % in the presence of autologous feeder cells. Several human monoclonal antibodies against HIV-1 [23] , severe acute respiratory syndrome [19] and influenza virus [23] have also been isolated using this method. In our experiments, the traditional EBV transformation method was optimized to an efficiency of 7.8 %, which enabled the generation of B-cell libraries for the subsequent isolation of HIV-1 envelope-specific B cells. In addition, the M-280 beads we used for the isolation of HIV-1-specific cells were 2.8 µm in diameter. This is much larger than the commonly used MACS beads, which are 50 nm in diameter [17] . We found that M-280 beads worked as efficiently as MACS beads for the enrichment of antigen-specific B cells and could be detached easily. The bound cells could be quickly visualized using a light microscope, which then facilitated the process of cell panning.
The cells became a homogeneous population after four rounds of panning and carried limited mutations in VH and VL. LCL-P4 cells bound other strains of gp140 trimers besides the gp140 YU2 trimer. However, LCL-P4 cells did not show any neutralizing activity based on a standardized TZM-bl cell line assay (data not shown). Considering that the neutralizing profile somewhat correlated with antibody affinity maturation, as shown by the bNab b12 [23, 24] , it will be interesting to investigate whether antibody affinity maturation can occur in LCL-P4 cells by artificially expressing AID, followed by affinity-based isolation of cells. This may provide further insights into the process of bNAb HIV-1 vaccine design. Since the LCL-P4 cells express high levels of MHCII and other co-stimulators, this cell line might be useful as antigen-presenting cells or as a tool in cell-based vaccine development. In summary, our method to isolate an HIV-1-specific naïve B-cell line provides a model for further study of naïve B-cell activation and maturation in vitro. This work may be extended to the isolation of other antigens from pathogens or auto-immune diseases.
METHODS Preparation of concentrated virus
Infectious EBV stocks were prepared as previously reported, with minor modifications [16, 25] . Briefly, after inoculation, the EBV-producing marmoset B95.8 cells were seeded at 10 6 cells ml À1 and incubated at 37 C under 5 % CO 2 for 4 days in Iscove's modified Dulbecco's medium (IMDM) complemented with 10 % heat-inactivated (w/v) FBS, 1 % (v/v) penicillin-streptomycin and 35 ng 12-O-tetradecanoylphorbol-13-acetate ml
À1
. After centrifugation at 800 g for 5 min, the supernatant was passed through a 0.45 µm filter. The EBV-containing supernatant was loaded into Centricon Plus-70 units (100 000 MW cut-off, Millipore) and centrifuged at 3200 g for 45 min with the minimal retention volume remaining. The EBV-containing concentrate was resuspended with fresh IMDM to 10 % of the original volume. Aliquots of 1 ml per vial were stored at À80 C.
Isolation of human naïve B cells
Primary PBMCs were isolated from buffy coats of healthy donors by Ficoll density centrifugation. B cells were isolated using a Human B Cell Isolation Kit (Miltenyi Biotec). Non-B cells were indirectly magnetically labelled with a cocktail of biotin-conjugated monoclonal antibodies and removed with microbeads. Memory B cells and naïve B cells were further separated with CD27 microbeads (Miltenyi Biotec). The purity of the cell populations was determined by flow cytometry.
Optimized B-cell immortalization method by EBV infection
Purified naïve B cells were suspended in 3 ml IMDM supplemented with 10 % (w/v) heat-inactivated fetal bovine medium, 100 units penicillin ml
À1
, 100 µg streptomycin ml
, 0.66 µg cyclosporine ml À1 , 2 µg CpG2006 ml À1 , 25 ng B-cell activating factor (BAFF) ml À1 , 2 µg Lipopolysaccharide (LPS) ml À1 and 5 ng IL-2 ml
. An equal volume of concentrated EBVcontaining supernatant was added to the cell suspension and mixed well. The sample was centrifuged at 500 g for 60 min at room temperature and then resuspended at a concentration of 10 6 cells ml
. Cells were seeded into 96-well U-bottom plates at a volume of 200 µl per well. Plates were incubated at 37 C under 5 % CO 2 . They underwent a half-media change every 7 days. After 3 weeks of culture, cells were transferred to a T75 flask for further growth. 
Enrichment of gp140 YU2 -based B cells
ELISA
To quantify the concentrations of IgG, IgM and IgA in the supernatant, goat anti-human IgG (Fcg fragment specific), goat anti-human IgM (Fc5µ fragment specific) and goat anti-human IgA (a-chain specific) antibodies were used for ELISA plate coating, respectively. HRP-conjugated goat anti-human IgG F(ab¢) 2 fragment-specific antibody was used as the secondary detection antibody. To test envelopespecific binding, gp140 YU2 , gp140 SF162 , gp120 and gp41 were coated onto an ELISA plate. HRP-conjugated goat anti-human IgG F(ab¢) 2 fragment-specific antibody was used as the secondary detection antibody for these ELISA assays. All antibodies were obtained from Jackson ImmunoResearch. 
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